BEIJING: Drug Regulatory Authority of Pakistan (DRAP) CEO Asim Rauf said on Wednesday that the Second SCO Pharmaceutical Cooperation Development Conference has demonstrated the commitment of member countries to foster global cooperation in the pharmaceutical industry.
He said that through this platform, SCO member nations aim to promote mutual benefits, encourage research and development collaboration, strengthen regulatory frameworks, and expand market access.
Addressing a conference in Suzhou, China, Asim Rauf highlighted Pakistan’s commitment to promoting pharmaceutical development and regulation.
In his address, he stressed the importance of cooperation among SCO member countries in ensuring drug safety and advancing research and development in the pharmaceutical sector.
With the world facing unprecedented challenges, including the COVID-19 pandemic, the need for partnership and collaboration in the pharmaceutical sector has become even more critical. Pakistan and other SCO countries are committed to working together to strengthen health systems, ensure the availability of essential medicines, and improve the overall well-being of their populations.
DRAP CEO Highlights Pakistan’s Achievements
The CEO took the opportunity to share the achievements of Pakistan in pharmaceutical regulation, underlining the measures taken by DRAP to streamline the drug approval process, enhance quality control steps, and promote transparency in the pharmaceutical industry.
He said that Pakistan has developed very rapidly in the field of regulation and the acceptance of its medicines is also increasing in the world. Particularly, during the pandemic, the Pakistani industry has done a lot of work, including starting the digitization process, introducing the CTD format, independent trials, automating, etc.
He said that Pakistan has witnessed a surge in its pharmaceutical exports as a result of these measures. Pakistan is ready to share the measures and experiences it has taken with other SCO member countries.
